Are you interested in developing a new bioproduct and attracted by the incredible potentials of new modalities like ATMPs, Cell and Gene Therapies, AAVs, oligonucleotides, multi-specificity antibodies, mRNA vaccines, and more? Despite the appeal of these new modalities, there is a significant risk of failure due to the many unknowns associated with these new technologies.

The needs of patients provide the impetus to challenge the notion of “this is the way we’ve always done it.”